Abbott Announces Collaboration with Syngene to Open Nutrition R&D Center

03-May-2012 - Abbott announced plans to establish its first nutrition research and development center in the country in collaboration with Syngene. The Abbott Nutrition R&D Center in India will focus on the development of science-based, affordable nutrition products for the country and enable the expansion of ...

Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for Peptide Hybrid

Program will Focus on the Potential Treatment of Diabetes

14-Sep-2009 - Amylin Pharmaceuticals, Inc. and Biocon, Limited announced that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic ...

Novozymes: Acquisition of enzyme activities from Biocon completed

02-Oct-2007 - Novozymes A/S has completed the acquisition of the enzyme activities of Biocon Limited, Bangalore, India. In reference to stock exchange announcement no.17 of July 18, 2007, the acquisition was subject to shareholders' approval and approval by the relevant Indian regulatory bodies, which have now ...

Novozymes acquires enzyme activities of Biocon, India

20-Jul-2007 - Novozymes A/S has signed a definitive agreement under which it will acquire the enzyme activities of Biocon Limited, Bangalore, India. Novozymes does not currently hold any stake in Biocon. The total consideration to be paid to Biocon will be Indian Rupees equivalent of USD 115m. The purchase ...

Syngene International and Innate Pharmaceuticals collaborate to develop virulence blockers

06-Sep-2006 - Syngene International Private Limited, a wholly owned subsidiary of Biocon Limited and Innate Pharmaceuticals AB have concluded a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease. Virulence blockers are a new class of ...

YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer

24-Jul-2006 - YM BioSciences Inc. reported that India's Drug Controller General has granted marketing approval to nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer. Biocon Biopharmaceuticals Ltd, a joint venture between Biocon and CIMAB SA (Havana, Cuba), has rights to the ...